Ashurst Hong Kong acted for Nomura International (Hong Kong) Limited in the HK$140 million placement of new shares by HKSE-listed Golden Meditech Holdings Limited to Atlantis Investment Management (Hong Kong) Limited.  Nomura acted as the placing agent in the placement. Golden Meditech is a leading integrated-healthcare device and service operator in the PRC. Golden Meditech intends to apply the net proceeds from the placement for the acquisition of shares in NYSE-listed China Cord Blood Corporation by way of a general offer.

The Ashurst team was led by Hong Kong-based corporate partner Jonathan Hsui, assisted by counsel Heidi Lee. Counsel Ethan Perry led with respect to US securities law matters.